(8) Matthew Tucker, Addison Keely, Joo Young Park, Manuela Rosenfeld, et al (2023) Intranasal GHK peptide enhances resilience to cognitive decline in aging mice bioRxiv [Preprint], 2023 Nov 17:2023.11.16.567423
Targeting multiple homeostasis-maintaining systems by ionophore nigericin is a novel approach for senolysis
While effective for improving skin texture and addressing sun damage, they work through a fundamentally different mechanism than copper peptides
Unlike fine lines that may improve quickly, established expression lines need time for accumulated collagen to fill in grooved skin and for improved elasticity to prevent further deepening
Product Attributes CAS # : 2103905-91-3 Molecular Formula : C201H325N65O67 Sequence (AA) : (D-Arg)9-LTLRKEPASEIAQSILEAYSQNGWANRRSAGGKRPPPRRRQRRKKRG Molecular Weight : ~4598 g/mol PubChem CID : N/A (peptide not indexed) Half-Life : ~2-4 hours Synonyms : Proxofim, FOXO4-D-Retro-Inverso, FOXO4-p53 Interfering Peptide Type : Synthetic D-retro-inverso peptide (senolytic research compound) Research Focus : Longevity & Senescence, Cellular Repair Scientific References Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Animal | In vitro FOXO4-DRI peptide selectively induces apoptosis in senescent cells Animal | In vitro Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration Animal | In vitro Cellular senescence: Defining a path forward Observational | Animal | In vitro The role of senescent cells in ageing Animal | In vitro FOXO4 peptide disrupts FOXO4-p53 interaction to target senescent cells Animal | In vitro Senolytic therapy alleviates age-associated bone loss in mice Animal | In vitro Therapeutic interventions for aging: the case of cellular senescence Observational | Animal | In vitro Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator
Yasuno F, Nakagome K, Omachi Y et al (2025) Leptin and inflammatory pathways in the Alzheimers disease continuum: implications for glial activation and neuropsychiatric symptoms
